USPTO serial 78530142
GP
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- GUSTASON, ANNE C
- Law office
- LAW OFFICE 117 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with GP?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Mary Beth Ciocco
MARY BETH CIOCCO MARY BETH CIOCCO LLC22255 CTR RIDGE RD STE 106ROCKY RIVER, OH 44116-3950UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for use in chemotherapy, herbal supplements, pharmaceutical preparations for the treatment of the digestive system, respiratory system, immune system, circulatory system, nervous system, namely, antimicrobial preparations for inhibiting microbiological decomposition in food, beverages, animal feed and pharmaceuticals, bismuth preparations for pharmaceutical purposes, inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders, pharmaceutical antitussive-cold preparations, pharmaceutical anti-allergic preparations and substances, anticoagulants, antidepressants, appetite suppressants, for use in chemotherapy, for the treatment of gout, for the treatment of heart rhythm disorders, for the treatment of infectious diseases, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents, acting on the central nervous system, for the treatment of gastro-intestinal diseases, for inhalation for the treatment of pulmonary hypertension, for ocular or intraocular surgery, for the treatment of hormonal disorders and the prevention of osteoporosis, for treating allergic rhinitis and asthma, for treating diabetes, for treating skin disorders, for use in dermatology, for wounds, for use in urology, against dry skin caused by pregnancy, chloasma, for hydrating the skin during pregnancy, for pregnancy blemishes, for preventing skin blemishes during pregnancy, to prevent stretch marks, to prevent swelling in the legs, potassium preparations, vitamin and mineral preparations for use as ingredients in the food and pharmaceutical industry, dietary supplement drink mixes, raw medicines, namely, anti allergic medicines, medicines for the treatment of gastrointestinal diseases, Chinese patent medicines for the treatment of the digestive system, respiratory system, immune system, nervous system, namely, antimicrobial preparations for inhibiting microbiological decomposition in food, beverages, animal feed and pharmaceuticals, bismuth preparations for pharmaceutical purposes, inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders, pharmaceutical antitussive-cold preparations, pharmaceutical anti-allergic preparations and substances, anticoagulants, antidepressants, appetite suppressants, for use in chemotherapy, for the treatment of gout, for the treatment of heart rhythm disorders, for the treatment of infectious diseases, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents, acting on the central nervous system, for the treatment of gastro-intestinal diseases, for inhalation for the treatment of pulmonary hypertension, for ocular or intraocular surgery, for the treatment of hormonal disorders and the prevention of osteoporosis, for treating allergic rhinitis and asthma; for treating diabetes; for treating skin disorders; for use in dermatology; for wounds; for use in urology; against dry skin caused by pregnancy; chloasma; for hydrating the skin during pregnancy, for pregnancy blemishes, for preventing skin blemishes during pregnancy, to prevent stretch marks, to prevent swelling in the legs, potassium preparations, vitamin and mineral preparations for use as ingredients in the food and pharmaceutical industry, biochemical preparations for medical use, blood substitutes for humans, alcohol for topical use, cachou for pharmaceutical purposes, diagnostic reagents for medicinal use, baby food, medicated candy, antimicrobial coatings to prevent the growth of mold, mildew, bacteria and fungus on various surfaces, veterinary preparations, namely, anti-infective products, bacterial and bacteriological preparations, bacteriostats, biochemical preparations, biological and chemical preparations and reagents, diagnostic preparations, electrophoresis gels, ferments, nucleic acid sequences and chemical reagents, plant extracts, reagents and media, pain relief medication, for treatment of intestinal bacteria, veterinary vaccines, yeast or yeast extracts, insect repellents, sanitary napkins, traditional Chinese medicine packs comprised of antimicrobial preparations for inhibiting microbiological decomposition in food, beverages, animal feed and pharmaceuticals, bismuth preparations for pharmaceutical purposes, inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders, pharmaceutical antitussive-cold preparations, pharmaceutical anti-allergic preparations and substances, anticoagulants, antidepressants, appetite suppressants, for use in chemotherapy, for the treatment of gout, for the treatment of heart rhythm disorders, for the treatment of infectious diseases, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; acting on the central nervous system, for the treatment of gastro-intestinal diseases, for inhalation for the treatment of pulmonary hypertension, for ocular or intraocular surgery, for the treatment of hormonal disorders and the prevention of osteoporosis, for treating allergic rhinitis and asthma, for treating diabetes, for treating skin disorders, for use in dermatology, for wounds, for use in urology, against dry skin caused by pregnancy, chloasma, for hydrating the skin during pregnancy, for pregnancy blemishes; for preventing skin blemishes during pregnancy; to prevent stretch marks; to prevent swelling in the legs, potassium preparations, vitamin and mineral preparations for use as ingredients in the food and pharmaceutical industry, traditional Chinese medicines, namely medicated balms, medicinal oils, capsules for medicines, medicinal teas, dietetic substances adapted for medical use, biological preparations for medical purposes, processed food adapted for medical purposes; menstrual symptom treatment preparations, vitamins, vitamin preparations, ginseng, swallow-nests, herbal medicine, Chinese patent medicines, medicinal beverages, fungicides, herbicides; dietetic preparations for health purpose, deer tendons, deer penises, deer tails, deer antlers, slices of antler, all adapted for medical purpose, dressings for wounds, burns, surgery, haemostatic pencils, fillings for teeth, medical adhesive tapes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 4, 2008 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Aug 4, 2008 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jan 7, 2008 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 7, 2008 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 7, 2008 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 7, 2008 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Dec 20, 2007 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Dec 10, 2007 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Dec 10, 2007 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 19, 2007 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Nov 19, 2007 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 19, 2007 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Nov 18, 2007 | ALIE | ASSIGNED TO LIE | — |
| Aug 14, 2007 | PGRR | PETITION GRANTED - RESPONSE RECEIVED | — |
| Aug 3, 2007 | APET | ASSIGNED TO PETITION STAFF | — |
| Jun 21, 2007 | PETR | PETITION TO REVIVE-RECEIVED | — |
| Jun 21, 2007 | PAPER RECEIVED | — | |
| Jun 19, 2007 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 19, 2007 | FAXX | FAX RECEIVED | — |
| Jun 19, 2007 | FAXX | FAX RECEIVED | — |
| Jun 19, 2007 | FAXX | FAX RECEIVED | — |
| Jun 19, 2007 | FAXX | FAX RECEIVED | — |
| Oct 17, 2006 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Oct 17, 2006 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Mar 19, 2006 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 19, 2006 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 6, 2006 | ZZZY | PREVIOUS ACTION COUNT WITHDRAWN | — |
| Jan 27, 2006 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 17, 2006 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 17, 2006 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 15, 2005 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 15, 2005 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 14, 2005 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 21, 2004 | NWAP | NEW APPLICATION ENTERED | — |